Endothelin-3: selectivity as an anti-aggregatory peptide in vivo.
Endothelin-3 (1 nmol/kg) given i.v. to anaesthetised rabbits significantly inhibited ADP-induced ex vivo platelet aggregation, while causing only a transient decrease in blood pressure and no change in heart rate. Pretreatment with piroxicam (14 mumol/kg) abolished the anti-aggregatory effect. Thus, endothelin-3, while not inhibiting rabbit platelets in vitro, can induce the release of a cyclo-oxygenase produce, probably prostacyclin, which inhibits ex vivo aggregation. Unlike endothelin-1, this was achieved with minimal effect on the haemodynamics.
Lidbury
P S
PS
William Harvey Research Institute, St. Bartholomew's Hospital Medical College, London, U.K.
Thiemermann
C
C
Thomas
G R
GR
Vane
J R
JR
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D016232:Endothelins; D006339:Heart Rate / Q000187:drug effects; D066298:In Vitro Techniques; D008297:Male; D010455:Peptides / Q000494:pharmacology*; D010894:Piroxicam / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors; D011817:Rabbits; D013997:Time Factors
D016232:Endothelins; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D010894:Piroxicam